REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

23h ago, source:

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.

REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures

7d ago, source:

A look at the shareholders of REGENXBIO Inc. ( NASDAQ:RGNX) can tell us which group is most powerful. And the group that ...

Where Regenxbio Stands With Analysts

12d ago, source:

Analysts' ratings for Regenxbio (NASDAQ:RGNX) over the last quarter vary from bullish to bearish, as provided by 9 analysts.

REGENXBIO, Inc.

2mon ago, source: CNN

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product ...

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants

1mon ago, source: WTNH

ROCKVILLE, Md., March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy ...

RCKT Rocket Pharmaceuticals, Inc.

5d ago, source: Seeking Alpha

and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

28d ago, source: Stockhouse

ROCKVILLE, Md., March 28, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and tolerability of a single ...

REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL

1mon ago, source: Nasdaq

ROCKVILLE, Md., March 5, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 in ...

Regenxbio Inc

3d ago, source: U.S. News & World Report

Semiconductor ETFs can help investors tap into tailwinds such as demand from artificial intelligence, government grants and a re-shoring movement.

Regenxbio Inc RB0

6d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...